exemestane

(redirected from Aromasin)
Also found in: Medical.
Translations

exemestane

n exemestano
References in periodicals archive ?
"Hormonal medications such as tamoxifen and aromatase inhibitors (Arimidex, Aromasin, and Femara) interfere with estrogen and prevent it from activating cancer cells.
M2 PHARMA-February 28, 2019-Breckenridge awarded US FDA's final approval for Exemestane Tablets (Aromasin) ANDA
Global Banking News-February 28, 2019-Breckenridge awarded US FDA's final approval for Exemestane Tablets (Aromasin) ANDA
M2 EQUITYBITES-February 28, 2019-Breckenridge awarded US FDA's final approval for Exemestane Tablets (Aromasin) ANDA
Her home medications included amiodarone, aromasin, aspirin, carvedilol, diltiazem, pantoprazole, sevelamer hydrochloride, cinacalcet, and albuterol.
The company said it recently received Food and Drug Administration approval for the product, a generic version of Aromasin from Pfizer Inc.
Hormone type Tamoxifen 1442 (90.4%) Letrozole 82 (5.1%) Tamoxifen/letrozole 37 (2.3%) Aromasin 26 (1.6%) Tamoxifen/Aromasin 6 (0.4%) Tamoxifen/decapeptyl 3 (0.2%) Note: Table made from bar graph.
The global breast cancer therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes - brand name (chemical name) such as antimetabolites - Gemzar (gemcitabine), aromatase inhibitors - Afinitor (everolimus), Arimidex (anastrozole), Aromasin (exemestane), Femara (leterozole), Ibrance (palbociclib); Her2 Inhibitors - Herceptin (trastuzumab), Kadcyla (ado-trastuzumab emtansine), Perjeta (pertuzumab), Tykerb (lapatinib); Hormone receptors - Fareston, Faslodex, Zoladex; and Mitotic inhibitors - Halaven (eribulin), Ixempra (ixabepilone), Taxotere (docetaxel), and forecasts growth trends (CAGR% - 2016 to 2020).
According to the NOV the FDA issued to Pfizer in 2009, one of Pfizer's sponsored links provided incomplete content about dosage information for their product Aromasin. The FDA alleged in this letter that Aromasin's sponsored link broadened the indication, implying that the promoted drug was available for treatment of the broader female population, although the drug treatment was limited to only a specific type of patient, ie, postmenopausal women.
It will collect outcome data for patients with metastatic breast cancer receiving everolimus with another drug, exemestane (Aromasin).
Some drugs also may increase the risk of osteoporosis, including corticosteroids such as prednisone, aromastase inhibitors such as anastrozole (Arimidex) and exemestane (Aromasin), which are used to prevent breast cancer recurrence, and some epilepsy medications.